Almost three quarters of women with rheumatoid arthritis worldwide suffer pain daily

June 16, 2010

Rome, Italy, Wednesday 16 June 2010: Almost three quarters (72%) of women with Rheumatoid Arthritis (RA) suffer pain daily, despite the fact that three quarters (75%) receive pain relief medication, according to a new study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Furthermore the physical pain appears to affect women to such an extent that it impacts negatively on emotional and social aspects of their lives.

Key results from data collected across seven countries (UK, France, Germany, Italy, Spain, USA and Canada) highlighted the health-related emotional, social and physical impact of RA on women's lives. Women with RA reported suffering feelings of detachment and isolation and said hat their condition had negatively affected intimate relationships; with 40% of single women stating that it was more challenging to find a partner and 22% of divorced or separated respondents indicating that RA played a role in their decision to separate from their partner. Sixty eight percent of women with RA reported concealing their pain from those closest to them, and 67% said they constantly look for new ideas to address the pain they suffer.

"These data confirm that pain is a paramount issue for women with RA, fundamentally striking at the heart of their physical, social and emotional wellbeing. The research highlights the complexity of the management of RA, and the pain associated with RA, over and above basic symptom control," said Professor Paul Emery, President of EULAR and arc Professor of Rheumatology, Leeds Institute of Molecular Medicine, University of Leeds, UK. "The adoption of treatment pathways and strategies to reduce pain, reinstate productivity at work and manage the social impact of RA is of huge importance in the clinical management of this patient population."

The survey further explored the negative impact of the disease and pain on respondents' productivity at work with 71% of those who were employed at the time of the survey (n=1,108), reporting they were less productive at work because of their RA. Many respondents reported that RA had a long term effect on their work life, with 23% of respondents stopping work altogether and 17% of respondents reporting a switch to part-time employment as a result of their RA.

"PARE (People with Arthritis and Rheumatism in Europe) believes firmly that putting the patient at the centre of all discussions on the management of rheumatic conditions is imperative. The results of this study highlight that a continuing dialogue between Healthcare practitioners and patients is essential for long term conditions such as RA," said Neil Betteridge, Vice President, PARE and Chief Executive Officer of Arthritis Care in the UK. "PARE has developed a set of eight practical recommendations* organising patient involvement in clinical research which we hope will enable the successful inclusion of a patient perspective in future research projects, in particular in the context of EULAR studies. These recommendations follow a progressive model from which we believe the whole world can learn."

27,459 women aged 25-65 (mean age 46) were recruited for the study via an online research panel, 1,958 of these participants completed the questionnaire between 30th July and 31st August 2009. Seventy five percent had been formally diagnosed with RA for longer than one year, and 69% self reported moderate to severe RA disease activity.
-end-
* Abstract SP0094 ("EULAR recommendations for the inclusion of patient representatives in scientific projects - a EULAR initiative") is being presented as part of a Joint Clinical / HPR / PARE Session in Room 10 DE on Friday 18 June from 13:45. Abstract Number: OP0002-PARE

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office on the 1st floor in Hall 5 of the Congress Centre during EULAR 2010 or on:
Email: eularpressoffice@uk.cohnwolfe.com
Rory Berrie: Onsite tel: +44 7901 513 297
Caroline Butt: Onsite tel: +44 7789 270 392

About EULAR

European League Against Rheumatism

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.